Summary
Despite the advances achieved since the introduction of chlprpromazine, schizophrenia may respond inadequately to standard drug treatments. The reasons for this include noncompliance, poor tolerance and the development of distressing side effects or the resistance of the illness itself. Treatment-resistant schizophrenia is increasingly the focus of new research developments.
The older or classic antipsychotic drugs have a broad spectrum of action on central and peripheral nervous system receptors. Their action on dopamine receptors was an early clue to the pathogenesis of schizophrenia. More recently, multiple subtypes of dopamine receptors have been identified. These, plus serotonin receptors, have been identified in brain structures thought to be implicated in schizophrenic illnesses. Atypical antipsychotic agents whose pharmacological action is either more specific, or which have novel receptor binding profiles show characteristic effects in both animal models and clinically. These drugs may improve symptoms in otherwise resistant illness or where intolerance prevents the use of standard treatments.
There are a number of adjunctive somatic treatment strategies using established agents such as lithium and electroconvulsive therapy the use of which is now being explored systematically. The most exciting current development is the re-emergence of clozapine as a highly effective atypical antipsychotic drug which can be used safely if special surveillance is undertaken to monitor for its potentially severe toxic effects.
These recent advances offer hope of improvement in the prognosis of people suffering from severe and intractable forms of schizophrenia.
Similar content being viewed by others
References
Ackenheil M. The differential therapeutic outcome in schizophrenia of compounds acting at D2 receptors. Clinical Neu-ropharmacology 15 (Suppl. 1): 464–465, 1992
American Psychiatric Association (APA). Task force on late neurological effects of antipsychotic drugs: tardive dyskinesia. American Journal of Psychiatry 137: 1163–1172, 1980
Anden NE, Stock G. Effect of clozapine on the turnover of dopamine in the corpus striatum and the limbic system. Journal of Pharmacology 25: 346, 1973
Barnes TRE, Kidger, Gore SM. Tardive dyskinesia: a three year follow up study. Psychological Medicine 13: 71–81, 1983
Bratfos O, Haug JO. Comparison of sulpiride and chlorpromazine in psychoses, a double blind multi centre trial. Acta Psychiatrica Scandanavica 60: 1–9, 1979
Castle D, Sham P, Wessley S, Murray RM. The subtyping of schizophrenia in men and women: a latent class analysis. Psychological Medicine, submitted for publication, 1993
Costall B, Naylor RJ, Tyers MB. Recent advances in the neu-ropharmacology of 5HT-3 agonists and antagonists. Reviews in the Neurosciences 2: 41–65, 1988
Christisen GW, Kirch DG, Wyatt RJ. When symptoms persist: choosing among alternative somatic treatments for schizophrenia. Schizophrenia Bulletin 17: 217–245, 1991
Cohen JD, Van Putten T, Marder S, Berger PA, Stahl SM. The efficacy of piquindone, a new atypical neuroleptic, in the treatment of the positive and negative symptoms of schizophrenia. Journal of Clinical Psychopharmacology 7: 324–328, 1987
Cole JD, Goldberg SC, Klerman GL. Phenothiazine treatment in acute schizophrenia. Archives of General Psychiatry 10: 246–261, 1964
Committee on Safety of Medicines. Clozaril-induced neutropenia and the clozaril patient monitoring service. Current Problems 30: 1, 1990
Chouinard G. Early phase 2 clinical trials of remoxipride with measurement of prolactin and neuroleptic activity. Journal of Clinical Psychopharmacology 7: 159–164, 1987
Crocq MA, Mant R, Asherson P, Williams J, Hode Y, et al. Association between schizophrenia and homozygosity at the dopamine D3 receptor gene. Journal of Medical Genetics 29: 858–860, 1992
Crow TJ, MacMillan JF, Johnson AL, Johnston E. The Northwick Park study of first episodes of schizophrenia 2. British Journal of Psychiatry 148: 120–127, 1986
Davis JM. Overview: maintainance therapy in psychiatry 1. Schizophrenia. American Journal of Psychiatry 132: 1237–1245, 1975
Davis JM. Treatment of schizophrenia. Current Opinion in Psychiatry 4: 28–33, 1991
Ereshefsky L, Watanabe MD, Tran-Johnson TK. Clozapine: an atypical antipsychotic agent. Clinical Pharmacology 8: 691–709, 1989
Farde L, Weisel F-A, Jansson P, Uppfeldt G, Wahlen A, et al. An open trial of raclopride in acute schizophrenia. Confirmation of D2 receptor occupancy by PET. Psychopharmacology 94: 1–7, 1988
Farde L, Weisel F-A, Stone-Elander S, Halldin C, Nordstrom A-L, et al. D2 dopamine receptors in neuroleptic naive schizophrenic patients: a positron emission tomography study with [11 C] raclopide. Archives of General Psychiatry 47: 213–219, 1990
Farde L, Nordstrom A-L. PET analysis indicates atypical central dopamine receptor occupancy in clozapine treated patients. British Journal of Psychiatry (Suppl. 17): 30–33, 1992
Farmer AE, McGuffin P, Gottesman II. Searching for the split in schizophrenia: a twin study approach. Psychiatry Research 13: 109–118, 1984
Farmer AE, McGuffin P. The pathogenesis and management of schizophrenia. Drugs 35: 177–185, 1988
Fitton A, Heel RC. Clozapine: a review of its pharmoclogical properties and therapeutic use in schizophrenia. Drugs 40: 722–747, 1990
Gerlach J. New antipsychotics: classification, efficacy and adverse effects. Schizophrenia Bulletin 17: 289–309, 1991
Gill M, McGuffm P, Parfitt E, Mant R, Asherson P, et al. A linkage study of schizophrenia with DNA markers from the long arm of chromosome 11. Psychological Medicine, in press, 1993
Healy D. Neuroleptics and psychic indifference: a review. Journal of the Royal Society of Medicine 82: 615–619. 1989
Hirsch SR, Gaind R, Rohde PD, Stevens BC, Wing JK. Outpatient maintainance of chronic schizophrenic patients with long acting fluphenazine: double blind placebo trial. British Medical Journal 1: 633–637, 1973
Hogarty GE, Goldberg SC, Schooler NR, Ulrich RF. Collaborative Study Group. Drugs and sociotherapy in the aftercare of schizophrenic patients 2. Two year relapse rates. Archives of General Psychiatry. 31: 603–608, 1974
Hogarty GE, Schooler NR, Ulrich T, Mussare F, Ferro P, et al. Fluphenazine and social therapy in the aftercare of schizophrenic patients. Archives of General Psychiatry 36: 1283–1294, 1979
Jellinek T, Gardos G, Cole JO. Adverse effects of antiparkinson-ian drug withdrawal. American Journal of Psychiatry 138: 1567–1571, 1981
Johnson DAW. Prevalence and treatment of drug induced extra-pyramidal symptoms. British Journal of Psychiatry 132: 27–30, 1978
Johnson DAW. Drug treatment of schizophrenia. In Bebbington & McGuffin (Eds) Schizophrenia the major issues, pp. 158–171, Heineman Professional Publishing, Oxford, 1988
Johnson DAW. Studies of depressive symptoms in schizophrenia. British Journal of Psychiatry 139: 89–101, 1981
Johnstone EC, Crow TJ, Frith CD, Carney MWP, Price JS. Mechanism of the antipsychotic effect in the treatment of acute schizophrenia. Lancet 1: 848–857, 1978
Kane JM. Clinical efficacy of clozapine in treatment refractory schizophrenia: an overview. British Journal of Psychiatry 160 (suppl. 17): 41–45, 1992
Kane J, Honigfeld G, Singer J, Melzer H. Clozaril Collaborative Study Group: clozapine for the treatment of resistant schizophrenia: a double blind comparison with chlorpromazine. Archives of General Psychiatry 45: 789–796, 1988
Krupp P, Barnes P. Clozapine-associated agranulocytosis: risk and aetiology. British Journal of Psychiatry 160 (Suppl. 17): 38–40, 1992
Leff JP, Wing JK. Trial of maintainance therapy in schizophrenia. British MedicaUournal 3: 599–604, 1971
Lewander T. Differential development of theurapeutic drugs for psychosis. Clinical Neuropharmacology 15 (Suppl. 1): 654–655, 1992
Lieberman JA, Alvir JMJ. A report of Clozapine induced agran-ulocytosis in the United States. Incidence and risk factors. Drug Safety 7 (Suppl.): 1–2, 1992
McClelland HA, Blessed B, Bhater S. The abrupt withdrawal of antiparkinsonian drugs in schizophrenic patients. British Journal of Psychiatry 124: 151–159, 1974
Marder SR, Van Putten T. Who should receive clozapine?. Archives of General Psychiatry 45: 789–796, 1988
Moises HW, Gelernter J, Giuffra LA, Zarcone V, Wetterburg L. No linkage between D2 dopamine receptor gene region and schizophrenia. Archives of General Psychiatry 48: 643–647, 1991
Meltzer HY, Burnett S, Bastani B, Ramirez LF. Effects of six months of clozapine treatment in the quality of life of schizophrenic patients. Hospital and Community Psychiatry 41: 892–897, 1990
Munetz MR, Cornes CL. Akathisia, pseudoakathisia and tardive dyskinesia. Comprehensive Psychiatry 23: 345–352, 1982
Naber D, Holzbach R, Perro C, Hippius H. Clinical management of clozapine patients in relation to efficacy and side effects. British Journal of Psychiatry 160 (Suppl. 17): 54–59, 1992
Owens F, Cross AJ, Crow TJ, Longden A, Pulter M, et al. Increased dopamine receptor sensitivity in schizophrenia. Lancet 2: 223–235, 1978
Peroutka SJ, Snyder SH. Relationship of neuroleptic drug effects on brain dopamine, serotonin, alpha-adrenaergic and histamine receptors to clinical potency. American Journal of Psychiatry 137: 1518–1519, 1980
Reynolds GP. Increased concentration and lateral asymmetry of amygdala dopamine in schizophrenia. Nature 305: 527–529, 1983
Safferman A, Lieberman J, Kane J, Szymanski S, Kinon B. Update on the clinical efficacy and side effects of Clozaril. Schizophrenia Bulletin 17: 247–261, 1991
Schmutz J. Neuroleptic piperazinyl-dibenzo-azepines. Arzniemittel-Forschung 25: 712–720, 1975
Schooler NR, Levine J, Sever JB, Bruazer B, DiMascio A, et al. Prevention of relapse in schizophrenia. Archives of General Psychiatry 37: 16–24, 1980
Schwarz JC. Multiple dopamine receptors: functional implications. In Proceedings of the 18th Collegium Internationale Neuropharmacologicum Congress, Vol. 15, Suppl. 1, part A, Raven Press, New York, 1992
Sharma R. Atypical antipsychotics. Current Opinion in Psychiatry 2: 49–53, 1989
Siris SG, Adan F, Cohen M, Mandeli J, Aronson A, et al. Targetted treatment of depression-like symptoms in schizophrenia. Psychopharmacology Bulletin 23: 85–89, 1987
Smith JM, Baldessarini RJ. Changes in the prevalence severity and recovery in tardive dyskinesia with age. Archives of General Psychiatry 37: 1368–1373, 1980
Sokoloff P, Giros B, Martres MP. Molecular cloning and characterization of a novel dopamine receptor (D3) as a target for neuroleptics. Nature 347: 146–151, 1990
Stahl SM, Wets KM. Clinical pharmacology of schizophrenia. In Bebbington & McGuffin (Eds) Schizophrenia: the major issues, pp. 135–157, Heineman Professional Publishing, Oxford, 1988
Stille G, Hippius H. Kritische Stellungsnahme zum begriff der Neuroleptika (anhand von pharmakologischen und klinischen befunden mit Clozapin). Pharmacopsychiatry 4: 182–191, 1971
Van Tol HHM, Bunzow JR, Guan HC, Sunahara RK, Seeman P, et al. Cloning of the gene for a human D4 receptor with high affinity for the antipsychotic clozapine. Nature 350: 610–614, 1991
VanValkenburg C, Kluznik JC, Merrill R. New uses of anticon-vulsant drugs in psychosis. Drugs 44: 326–335, 1992
Wadworth AN, Heel RC. Remoxipride. A review of its phar-macodynamic and pharmacokinetic properties, and therapeutic potential in schizophrenia. Drugs 40: 863–879, 1990
Williams P. An open trial of ondansetron (GR38032F) in the treatment of acute schizophrenia. Schizophrenia Research 3: 48, 1990
Williams J, Farmer AE, Wessley S, Castle D, McGuffin P. Heterogeneity in schizophrenia: an extended replication of the hebephrenic-like(H) and paranoid like(P) subtypes. Psychiatry Research, submitted for publication, 1993
Wong DF, Wagner HN, Tune LE, Dannals RF, Godfrey D, et al. Positron emission tomography reveals elevated D2 receptors in drug naive schizophrenics. Science 234: 1558–1563, 1986
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Farmer, A.E., Blewett, A. Drug Treatment of Resistant Schizophrenia. Drugs 45, 374–383 (1993). https://doi.org/10.2165/00003495-199345030-00006
Published:
Issue Date:
DOI: https://doi.org/10.2165/00003495-199345030-00006